NASDAQ:ASRT Assertio Q2 2024 Earnings Report $0.62 -0.01 (-1.89%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.65 +0.03 (+5.18%) As of 04/25/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Assertio EPS ResultsActual EPS-$0.04Consensus EPS -$0.02Beat/MissMissed by -$0.02One Year Ago EPS$0.13Assertio Revenue ResultsActual Revenue$31.13 millionExpected Revenue$30.37 millionBeat/MissBeat by +$760.00 thousandYoY Revenue GrowthN/AAssertio Announcement DetailsQuarterQ2 2024Date8/7/2024TimeAfter Market ClosesConference Call DateWednesday, August 7, 2024Conference Call Time4:30PM ETUpcoming EarningsAssertio's Q1 2025 earnings is scheduled for Monday, May 5, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Assertio Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 7, 2024 ShareLink copied to clipboard.There are 8 speakers on the call. Operator00:00:00Thank you for standing by. My name is Mark, and I will be your conference operator. At this time, I would like to welcome everyone to the Assertio Holdings Second Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question and answer session. Operator00:00:26You. I would now like to turn the call over to Matt Kreps of Investor Relations. Matt, the floor is yours. Speaker 100:00:33Good afternoon, and thank you all for joining us today to discuss Certio's Q2 2024 Financials. The news release covering our results for this period is now available on the Investor Relations page of our website at investor. Assertiotx.com. I would encourage all of you to review the release and tables in conjunction with today's discussion. With me today are Brendan O'Grady, our Chief Executive Officer and Ajay Patel, Chief Financial Officer. Speaker 100:00:58In just a moment, Brendan will open the remarks and provide an overview of the business, then Ajay will cover our financial results and guidance. After that, we will take questions from our covering and research analysts. Please note that during this call, management will make projections and other forward looking statements regarding our future performance. Such forward looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in this afternoon's press release as well as Assertio's filings with the SEC. These and other risks are more fully described in the Risk Factors section and other sections of our Annual Report on Form 10 ks and in our Form 10 Q filings. Speaker 100:01:35Our actual results may differ materially from those projected in the forward looking statements. Assertio specifically disclaims any intent or obligation to update these forward looking statements, except as required by law. And with that, I will now turn the call over to Brendan. Please go ahead. Speaker 200:01:50Thanks, Matt. Welcome, everyone, to today's call, and thank you for joining us. As many of you already know, this is my first earnings call since I joined Assertio a little over 2 months ago and I'm very excited to be here. Over the past couple of months, I've been asked by a variety of stakeholders why I joined Assertio. I expect that question may come up today in Q and A, so I thought I would address this upfront. Speaker 200:02:13Over the past year, Assertio has navigated the impact of the loss of exclusivity on Edison, as well as the acquisition and integration of Spectrum that brought us Rolledon. These transformational events have allowed Assertio to reset. We have a solid balance sheet, modest debt on favorable terms, good assets led by a new growth driver in Rolledon, and a platform ready to scale with the addition of future assets that fit a well defined and proven commercial model. For all of these reasons, we are well positioned for growth and to deliver value for the patients and providers we serve as well as the shareholders and employees. Assertio is also an excellent match to the background and skill set that I have developed over my 30 plus years in the pharmaceutical industry. Speaker 200:03:01In particular, the 20 years I spent at Teva, which built a multi $1,000,000,000 branded specialty business mostly through acquisition, integration and focused go to market strategies. While much of my time at Teva was focused in specialty biologic and branded pharma segments, I also gained experience and delivered results in biosimilar and generic markets both inside and outside the U. S, giving me a breadth of experience across Assertio's current asset base. Lastly, I have significant relevant experience in acquiring and integrating new assets, which of course includes the due diligence in process. For all of these reasons, very simply put, Assertio needs and my skill set is a very good match, so here I am. Speaker 200:03:47I want to be clear as I speak with you today that we are not planning that I'm not planning any radical departures from the current strategy. Our focus will remain on steady execution, driving cash flow and identifying the next assets we can add to bring further scale to Assertio's platform. In doing so, we will bring greater value to our long term stakeholders. Now with that said, turning to performance, the Q2 continued the momentum from the Q1 and tracks well to our full year outlook. Rolvadon Q2 sales increased again quarter over quarter, driven by a 6th consecutive quarter of demand growth. Speaker 200:04:27I had the opportunity right after joining the company to meet with several customers and the feedback was overwhelmingly positive. Volvodone is well regarded by physicians, well tolerated by patients and stands out against the field of biosimilars. We are focused on using our unique position as a non biosimilar to offer stability and predictability to providers and patients and that message is resonating. Additionally, we completed enrollment of rolvedon same day dosing trial early in Q2 and expect to present the initial data at a major medical conference later this year. I'm excited about rolodont as it's going to play a key role for us over the next several years. Speaker 200:05:11Turning to Endocin, we currently have 1 generic competitor and our share in the market is holding at our internal target levels, which we are comfortable at. We are managing the loss of exclusivity and are working to maintain this volume at a competitive price. We have successfully rightsized our organization, cut cost and made sure we have the right team in place to deliver results under this evolving dynamic. In my prior role, I had the benefit of overseeing the largest generic portfolio on the planet and work with generics and late stage assets at many other points in my career. So this is familiar territory for me as we work to maximize our opportunity with this and other assets that have lost exclusivity. Speaker 200:05:53In addition, we are currently working as a team in assessing the rest of our existing assets, seeking either the potential for modest growth or continued cash flow delivery depending on their stage of life and market dynamics. As a result of this ongoing execution, we generated $7,400,000 in cash, driving total cash to more than $88,000,000 at the end of the quarter. While our working capital needs have increased with the addition of Rolledown, our cash balance provides a key advantage as we look to add accretive assets that fit our commercial model. And with that, I will turn Speaker 300:06:28the call over to A. J. To review the financials in more detail. J. Muse:] Thanks, Brendan. Speaker 300:06:33Today, I would like to cover our financial results for the Q2 of 2024. Before I begin, I want to note that my commentary similar to last quarter will focus on sequential comparisons Speaker 200:06:47for the Q1. Speaker 300:06:47Comparisons to prior year are less relevant given the acquisition of Spectrum and the generic competition of Indusent that occurred in the prior year Q3. Also, I want to remind everyone that compared to the prior year. For the Q2 of 2024, our total product sales were $30,700,000 down slightly from $31,900,000 in the Q1. The decline is due to the growth in Rovidone being offset by expected decline in INDOCIN as there is a difference in growth trajectory of Robidone in its life cycle compared to the erosion of INDOCIN, which went generic less than a year ago. Rovidone sales in the 2nd quarter were $15,100,000 up from $14,500,000 in the prior quarter. Speaker 300:07:48The increase is due to continued volume growth that was partially offset by lower net pricing. Demand volume for rovedon grew again sequentially and set another high during the Q2. Published ASP change during the quarter for Rovidone was in line with our expectations and we continue to have the 2nd highest ASP in the class. Indicine sales were $6,900,000 compared to $8,700,000 in the 1st quarter. Generic competition, which is still in its 1st year, continues to impact both volume and pricing. Speaker 300:08:27Reported gross margin in the 2nd quarter was 71% compared to 65% in the 1st quarter. Both quarters were impacted by purchase accounting inventory step up amortization for Rovidone, which is now complete. Excluding this step up amortization, gross margin in the 2nd quarter was 73% compared to 78% in the 1st quarter. The 2nd quarter was impacted by an increase in inventory write downs in late stage products, which had a 3 percentage point impact. Turning to operating expenses. Speaker 300:09:05SG and A expense was $18,400,000 in the 2nd quarter, down slightly from $18,500,000 in the 1st quarter. 2nd quarter SG and A expense benefited from a $1,900,000 gain on a settlement of insurance reimbursement claims, which was offset by higher legal spend on new and ongoing matters and other expenses. R and D expense in the Q2 was flat and primarily included costs for rovedon trials. On an adjusted basis, excluding stock compensation and depreciation expenses, total operating expenses were $17,700,000 in the 2nd quarter versus $18,000,000 in the 1st quarter. GAAP net income for the Q1 was a loss of $3,700,000 down from a loss of $4,500,000 in the Q1. Speaker 300:10:03Because GAAP net income includes a number of non cash expenses, we also use adjusted EBITDA as a good indicator of operating performance of the core business. Q2 adjusted EBITDA was a positive $5,000,000 compared to Q1 adjusted EBITDA of $7,400,000 The change was primarily due to the impact of lower product sales and increase in inventory write down expense. Please refer to our press release for additional reconciliation of our adjusted EBITDA results. Crossing over to cash flow and our balance sheet. We generated $7,400,000 in cash flow from operations in the 2nd quarter on top of the $7,500,000 in the 1st quarter. Speaker 300:10:51As we have previously noted, quarterly cash flows will fluctuate due to the timing of working capital, royalties and interest payments as well as shift in product mix from IndusInd to Robidone. Cash and short term investments at the end of the second quarter were 88,400,000 up from $80,700,000 in the 1st quarter and debt was unchanged at $40,000,000 In the Q2, we invested cash into short term investments, leading to a change in our balance sheet tables. Our total cash position referenced in our commentary today includes the line items cash and cash equivalents plus a new line item for short term investments. We are also maintaining our previously announced guidance for 2024, which provided for net product sales in a range of 110 dollars to $125,000,000 and adjusted EBITDA in a range of $20,000,000 to $30,000,000 With that, we will open the floor to questions from our covering research analyst. Operator, please go ahead with the instructions. Operator00:12:02We will now begin the question and answer session. Your first question comes from the line of Thomas Platten with Lake Street Capital Markets. Thomas, your line is now open. Speaker 400:12:25Hey, good afternoon. I appreciate you taking the questions. Brendan, maybe I could start with you. It's only been a couple of months, but I'm curious maybe if you could put some guardrails around what it was that excited you about the opportunity and what you've learned in the months you've been there that may or may not confirm what you thought or maybe made it better or worse, etcetera? Just trying to get some thoughts from you on that. Speaker 200:12:48Sure. Happy to, Thomas. Thanks for the question. So, I guess, maybe I'll answer the back half of the question and come back to the first part. So, after 71 days into the role, it's exactly what I thought it would be, I'm happy to say. Speaker 200:13:03And things are going according to how I thought they would go. And then I think I joined as I said in the beginning, I joined Assertio because I believe that there is an opportunity here to create great value. I think that everything that I said in my opening remarks about the balance sheet, about the people, about the commercial model, those have all been confirmed in my 1st 71 days. I think that the landscape in business development is starting to heat up a little bit. There's numerous potential deals out there to get. Speaker 200:13:40We'll see how those go. But I'm excited about Rolvadon. I think Rolvadon is growing nicely as we've shown. I think we'll continue to execute on Rolvedon. That will be our primary growth driver. Speaker 200:13:51There are other assets in the portfolio that I think we can get some modest growth of, as well as optimize some of the later stage assets. So, my take is the foundational business is stable and positioned to grow, and we can start adding to that and really position Assertio for growth going forward, which I'm very excited to do and very excited to be part of. Speaker 400:14:19And speaking of growth, you guys from a product sales perspective, you're $62,500,000 for the first half of the year, which would be about half of the top end of your guidance range. How are you thinking about modifying guidance as we go forward, if at all? Speaker 200:14:37So, I'll come back in November and give you a better take on that. Again, I'm 71 days in, so I want to make sure that I've got a good handle on where all of is. I think you just brought up a very good point, something that's fairly obvious. But we'll take a look at how the year is shaking out. And by the time we get to November, we will have completed 9 months of the year. Speaker 200:15:01So we'll take a look and see what we do with guidance at that point. Speaker 400:15:06Appreciate you taking the questions. Thanks so much. Speaker 200:15:09Sure. Thank you. Operator00:15:12Your next question comes from the line of Ram Selvaraju with H. C. Wainwright. Ram, your line is now open. Speaker 500:15:18Thanks so much for taking my questions and congrats on the fine performance in this quarter. Firstly, I was wondering if you could comment on your expectations regarding the number of generic competitors to Indocin that you expect to be on the market by the end of this year. If you can maybe give us some granularity on that, what your expectations are based on your internal projections? And the second question pertains to what may or may not be your overall strategy with regard to bringing in additional products. And if you anticipate these products to likely be more along the lines of products that you can promote on a virtual basis or if you are looking at any opportunities that would necessitate the deployment of a field sales force akin to what you're currently doing with Rolledon? Speaker 500:16:08Thank you. Speaker 200:16:11So, great questions. So, the question on generic competitors, this is always a tricky question because you never really know and I used to get this a lot on different assets when I was with Teva. But quite frankly, we expected another generic competitor on the market in July. That didn't happen. So we'll see. Speaker 200:16:32We don't really know much more than that other than the gold date came and went and that product has not been launched. So I guess you could say that every day that it's not, there's somewhat of a tailwind for indocin. Could we see another one by the end of the year? Potentially, our original thought was maybe we would see 2 or 3 generics on the market by end of this year. We may get lucky and we may just see the one. Speaker 200:17:01So it's hard to say, but our plan was for multiple. So, we'll see if there's any potential upside here, as we go through the year. But that's kind of how we're thinking about Indus and generics for the rest of the year. As far as overall product strategy, I mean, I think we're looking for something that capitalizes on our current commercial model. And we don't some of our later stage assets we do all non personal promotion. Speaker 200:17:31Rolodon actually, we as you know, we have a field force out there supporting Rolvedon. But a lot of assets require a little bit both field and omnichannel. So I don't think that we're looking for an asset that is exclusively one or the other. I think we're looking for an asset that builds on our capabilities, that is cash accretive, that has patent protection or exclusivity. I think those are the things that we're looking at and what we can execute with the cash reserves and balance that we have. Speaker 200:18:06So that's kind of where we're looking. And I don't think we're looking for an asset that requires a 500 to 1000 person sales force. I think we're looking at assets that really fit, our place in the market and where our core competencies are. Speaker 500:18:24Thank you. Sure. Operator00:18:29Your next question comes from the line of Nader Ramon with Maxim Group. Nader, Your line is now open. Speaker 600:18:36Hi. Thanks for taking my question and congrats on all the progress. Just sticking with the theme of BD, based on all the assets you sort of looked at thus far, what has been the gating factors in terms of closing and acquisition? Are you seeing valuations that are, in your opinion, too high? Or are you seeing do you think valuations for these assets are relatively appropriate currently? Speaker 600:19:00And what's sort of been stopping you from closing any of these acquisitions? And I guess my follow-up to that is also, what are you thinking of in terms of a structure of a transaction? Like how do you think of the relative value of using cash, equity or debt in a potential transaction? Speaker 200:19:16So I'll answer part 1 and I'll let A. J. Answer part 2. But as a buyer, valuations are always too high. So I'll just put that out there right now. Speaker 200:19:29But having said that, there are certainly things that are of interest to us that we believe are executable. And we're in active discussions with several different organizations and we'll see if any of those pan out. If they do, then we'll obviously come back with more detail. But I'm pleased with kind of what's in our BD view, so to say, and we'll see what comes out of it. There are some encouraging opportunities out there. Speaker 200:20:03I don't really want to say anymore. I can't really say anymore at this point. But there are things that we can do. And A. J, maybe that's what I'll hand it over to you and talk about how. Speaker 300:20:12Yes. Yes, Anas, thanks for the question. I'll probably echo what Brendan said in terms of how we're looking at assets that fit our capabilities. I think we're looking at acquisition size that fit our capabilities. Obviously, we'll start with from a capital perspective, we have several avenues, but we'll start with the lowest cost of capital, which for us will be our cash on our balance sheet. Speaker 300:20:34And I think from there, we have opportunities to look at either mix structured from a debt perspective. But I think we see ourselves utilizing cash first and then going down the line in terms of capital structure. Speaker 600:20:49Got it. Thank you for taking my questions. And once again, congrats on the progress. Speaker 200:20:54Thank you. Operator00:20:57Your next question comes from the line of Scott Henry with Alliance Group Partners. Scott, your line is Speaker 500:21:04now open. Speaker 700:21:05Thank you and good afternoon and congratulations, Brendan. Your first conference call almost over. Hopefully, I won't get too interesting. So for starters, Rolvedon, annualizing north of $60,000,000 in 2024, which is great. How when we think about 2025 and the competitive dynamics, would you still expect it to be a strong growth product at that stage? Speaker 700:21:40And by strong growth product, I think 20% or higher growth. Should we still think about it that way? And if you don't answer specifically, maybe if you could just talk about some of the factors that could tilt it higher or lower kind of than that threshold? Speaker 200:21:59Sure, Scott. Thank you for the question. And it's a good question. I mean, as you know, we are bullish on Rolled On. We think it has legs in the organization. Speaker 200:22:10We plan for it to be a growth asset, not for just this year, not just next year, but for the foreseeable future. So, yes, I do think that we'll see growth next year. And it's something that we constantly manage is that as we gain volume, you make you do different deals and put different contracts out there. So you have to balance the ASP erosion versus the volume growth. But I think we've got a good plan in place to do that. Speaker 200:22:40As I've looked at, the rest of this year and I look out through 2025, I see no reason why we can't continue to grow our rolloverdine. It's not a straight line growth though. It doesn't grow like that quarter over quarter. Some quarters will take bigger leaps than others. Traditionally, in the Q3, at least my experience has been in the oncology markets, you see somewhat of a flattening in Q3 just because a lot of patients doing chemotherapy schedule vacations and schedule their chemotherapy so they can have several weeks where they feel good to go on vacation with their family. Speaker 200:23:14So typically, Q3 can tend to be more of a flat quarter. But, yes, we see continued growth for rolvedon this year and next year and hopefully for the next several years. Speaker 700:23:26Okay, great. And my follow-up question maybe in multiple parts, but we'll see. For starters, OTREXUP and SYMPAZAN, any thoughts on how they did in the quarter? I didn't recall. We don't see the numbers in there, at least sequentially how they perform? Speaker 200:23:49Yes. So, I know A. J. Can give you the exact numbers, but just in general, those are a couple of the assets we're looking at as to what the potential is for those. I think that we're starting to see some modest regrowth of SYMPAZAN as we take a look at that as our kind of go to market strategy there and how we're getting the messaging out. Speaker 200:24:12SYMPAZAN is a great product and physicians love it, patients love it, caregivers love it. It occupies a very unique place in the market. And it's just a matter of making more physicians and patients aware of it. So we're looking at the most effective, most cost a SYMPAZAN, I think it's a great asset. In OTREXUP, that's just a kind of a matter of how we manage access against cost of goods so that patients have access to it and we can maintain or grow our share in that market as well. Speaker 200:24:46So both those are good assets for us. I think OTREXUP was relatively stable and flat from quarter to quarter and SYPAZAN we're starting to see some growth in the second half of the year. Speaker 300:24:58Yes, Scott. You'll see our 10 Q filed later today, but both of them in aggregate approximated 4,700,000 dollars And as I kind of said in my commentary, the entirety of our product portfolio revenue change between Q1 and Q2 was the plus and minus from Robidone and Hindustan. The rest of the product portfolio was fairly flat. Speaker 700:25:22Okay, great. And then you mentioned that the rolvedon same day dosing trial has completed enrollment, initial data expected later this year. Do you have a sense of that data already? If I recall, was that an unblinded trial? And I'm not asking you to disclose it, but I'd just like to be curious if you know, what is unknown about that data at this point in time? Speaker 200:25:53Yeah. So we haven't fully seen the data yet. So as I said, it will be presented at a major medical conference later this year. So we're still awaiting to see, the exact outcome of the data. What I will say is that this trial was never powered for a new indication, for same day dosing for rolvedon. Speaker 200:26:18We are hopeful that we will see some positive results that support same day dosing use. And we've submitted the abstract based on the preliminary data and more to come on that. But we're optimistic. Speaker 700:26:32Okay, great. Well, thank you for taking the questions. Absolutely. Operator00:26:39Your next question comes from the line of Jim Sidoti with Sidoti and Company. Jim, your line is now open. Speaker 500:26:46Hi. Thanks for taking the question. So just to follow-up on that same day dosing question. If the data is compelling, would you consider doing a larger trial to get the labeling? Speaker 200:27:00So Jim, thanks for the question. I mean, if the data is real compelling, we'll take a look at it and see if there is value in doing a larger trial, what that investment would be required to do that and the hopes of getting that not just added to guidelines, but adding it to our label. We'll see. We'll make that determination once we see the full results of the trial and obviously talk with some key opinion leaders and assess where we go from there. Speaker 500:27:29Okay. And for Robidone, A. J, were there any inventory step up charges in the quarter? Speaker 300:27:36There was an inventory step up charge. It was about $400,000 Speaker 500:27:42Okay. And can you just repeat what the write down charge you took was? Speaker 300:27:49Yes. The inventory write down charges that we took during the quarter were for our late stage product assets, and the increase quarter over quarter was approximately $1,000,000 Speaker 500:28:01Okay. All right. Thank you. Operator00:28:07That concludes our Speaker 200:28:17us today. As I said in my opening remarks, I'm excited to be here at Assertio and I hope that today's call has illustrated not only the solid execution and cash generating business that we have today, but also our commitment to finding the right assets to help move Assertio into the next chapter as we work to further scale the business and create value. We will be attending a number of conference and roadshow events in the coming months, and I look forward to the opportunity to engage with our stockholders. If you would like to arrange a meeting at one of these events or an update call with management, please contact Matt Kreps directly using his information provided in the press release and we will be happy to schedule a time. And thank you all once again for joining us today. Speaker 200:29:00Take care. Have a good evening. Operator00:29:03Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallAssertio Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsQuarterly report(10-Q) Assertio Earnings HeadlinesAssertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025March 20, 2025 | globenewswire.comAssertio Holdings price target lowered to $3.50 from $4 at H.C. WainwrightMarch 19, 2025 | markets.businessinsider.comFrom Social Security to Social Prosperity?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)Assertio price target lowered to $1.75 from $2.15 at Alliance GlobalMarch 14, 2025 | markets.businessinsider.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | msn.comAssertio Therapeutics (ASRT) Gets a Buy from Lake StreetMarch 13, 2025 | markets.businessinsider.comSee More Assertio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Assertio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assertio and other key companies, straight to your email. Email Address About AssertioAssertio (NASDAQ:ASRT), a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.View Assertio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 8 speakers on the call. Operator00:00:00Thank you for standing by. My name is Mark, and I will be your conference operator. At this time, I would like to welcome everyone to the Assertio Holdings Second Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question and answer session. Operator00:00:26You. I would now like to turn the call over to Matt Kreps of Investor Relations. Matt, the floor is yours. Speaker 100:00:33Good afternoon, and thank you all for joining us today to discuss Certio's Q2 2024 Financials. The news release covering our results for this period is now available on the Investor Relations page of our website at investor. Assertiotx.com. I would encourage all of you to review the release and tables in conjunction with today's discussion. With me today are Brendan O'Grady, our Chief Executive Officer and Ajay Patel, Chief Financial Officer. Speaker 100:00:58In just a moment, Brendan will open the remarks and provide an overview of the business, then Ajay will cover our financial results and guidance. After that, we will take questions from our covering and research analysts. Please note that during this call, management will make projections and other forward looking statements regarding our future performance. Such forward looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in this afternoon's press release as well as Assertio's filings with the SEC. These and other risks are more fully described in the Risk Factors section and other sections of our Annual Report on Form 10 ks and in our Form 10 Q filings. Speaker 100:01:35Our actual results may differ materially from those projected in the forward looking statements. Assertio specifically disclaims any intent or obligation to update these forward looking statements, except as required by law. And with that, I will now turn the call over to Brendan. Please go ahead. Speaker 200:01:50Thanks, Matt. Welcome, everyone, to today's call, and thank you for joining us. As many of you already know, this is my first earnings call since I joined Assertio a little over 2 months ago and I'm very excited to be here. Over the past couple of months, I've been asked by a variety of stakeholders why I joined Assertio. I expect that question may come up today in Q and A, so I thought I would address this upfront. Speaker 200:02:13Over the past year, Assertio has navigated the impact of the loss of exclusivity on Edison, as well as the acquisition and integration of Spectrum that brought us Rolledon. These transformational events have allowed Assertio to reset. We have a solid balance sheet, modest debt on favorable terms, good assets led by a new growth driver in Rolledon, and a platform ready to scale with the addition of future assets that fit a well defined and proven commercial model. For all of these reasons, we are well positioned for growth and to deliver value for the patients and providers we serve as well as the shareholders and employees. Assertio is also an excellent match to the background and skill set that I have developed over my 30 plus years in the pharmaceutical industry. Speaker 200:03:01In particular, the 20 years I spent at Teva, which built a multi $1,000,000,000 branded specialty business mostly through acquisition, integration and focused go to market strategies. While much of my time at Teva was focused in specialty biologic and branded pharma segments, I also gained experience and delivered results in biosimilar and generic markets both inside and outside the U. S, giving me a breadth of experience across Assertio's current asset base. Lastly, I have significant relevant experience in acquiring and integrating new assets, which of course includes the due diligence in process. For all of these reasons, very simply put, Assertio needs and my skill set is a very good match, so here I am. Speaker 200:03:47I want to be clear as I speak with you today that we are not planning that I'm not planning any radical departures from the current strategy. Our focus will remain on steady execution, driving cash flow and identifying the next assets we can add to bring further scale to Assertio's platform. In doing so, we will bring greater value to our long term stakeholders. Now with that said, turning to performance, the Q2 continued the momentum from the Q1 and tracks well to our full year outlook. Rolvadon Q2 sales increased again quarter over quarter, driven by a 6th consecutive quarter of demand growth. Speaker 200:04:27I had the opportunity right after joining the company to meet with several customers and the feedback was overwhelmingly positive. Volvodone is well regarded by physicians, well tolerated by patients and stands out against the field of biosimilars. We are focused on using our unique position as a non biosimilar to offer stability and predictability to providers and patients and that message is resonating. Additionally, we completed enrollment of rolvedon same day dosing trial early in Q2 and expect to present the initial data at a major medical conference later this year. I'm excited about rolodont as it's going to play a key role for us over the next several years. Speaker 200:05:11Turning to Endocin, we currently have 1 generic competitor and our share in the market is holding at our internal target levels, which we are comfortable at. We are managing the loss of exclusivity and are working to maintain this volume at a competitive price. We have successfully rightsized our organization, cut cost and made sure we have the right team in place to deliver results under this evolving dynamic. In my prior role, I had the benefit of overseeing the largest generic portfolio on the planet and work with generics and late stage assets at many other points in my career. So this is familiar territory for me as we work to maximize our opportunity with this and other assets that have lost exclusivity. Speaker 200:05:53In addition, we are currently working as a team in assessing the rest of our existing assets, seeking either the potential for modest growth or continued cash flow delivery depending on their stage of life and market dynamics. As a result of this ongoing execution, we generated $7,400,000 in cash, driving total cash to more than $88,000,000 at the end of the quarter. While our working capital needs have increased with the addition of Rolledown, our cash balance provides a key advantage as we look to add accretive assets that fit our commercial model. And with that, I will turn Speaker 300:06:28the call over to A. J. To review the financials in more detail. J. Muse:] Thanks, Brendan. Speaker 300:06:33Today, I would like to cover our financial results for the Q2 of 2024. Before I begin, I want to note that my commentary similar to last quarter will focus on sequential comparisons Speaker 200:06:47for the Q1. Speaker 300:06:47Comparisons to prior year are less relevant given the acquisition of Spectrum and the generic competition of Indusent that occurred in the prior year Q3. Also, I want to remind everyone that compared to the prior year. For the Q2 of 2024, our total product sales were $30,700,000 down slightly from $31,900,000 in the Q1. The decline is due to the growth in Rovidone being offset by expected decline in INDOCIN as there is a difference in growth trajectory of Robidone in its life cycle compared to the erosion of INDOCIN, which went generic less than a year ago. Rovidone sales in the 2nd quarter were $15,100,000 up from $14,500,000 in the prior quarter. Speaker 300:07:48The increase is due to continued volume growth that was partially offset by lower net pricing. Demand volume for rovedon grew again sequentially and set another high during the Q2. Published ASP change during the quarter for Rovidone was in line with our expectations and we continue to have the 2nd highest ASP in the class. Indicine sales were $6,900,000 compared to $8,700,000 in the 1st quarter. Generic competition, which is still in its 1st year, continues to impact both volume and pricing. Speaker 300:08:27Reported gross margin in the 2nd quarter was 71% compared to 65% in the 1st quarter. Both quarters were impacted by purchase accounting inventory step up amortization for Rovidone, which is now complete. Excluding this step up amortization, gross margin in the 2nd quarter was 73% compared to 78% in the 1st quarter. The 2nd quarter was impacted by an increase in inventory write downs in late stage products, which had a 3 percentage point impact. Turning to operating expenses. Speaker 300:09:05SG and A expense was $18,400,000 in the 2nd quarter, down slightly from $18,500,000 in the 1st quarter. 2nd quarter SG and A expense benefited from a $1,900,000 gain on a settlement of insurance reimbursement claims, which was offset by higher legal spend on new and ongoing matters and other expenses. R and D expense in the Q2 was flat and primarily included costs for rovedon trials. On an adjusted basis, excluding stock compensation and depreciation expenses, total operating expenses were $17,700,000 in the 2nd quarter versus $18,000,000 in the 1st quarter. GAAP net income for the Q1 was a loss of $3,700,000 down from a loss of $4,500,000 in the Q1. Speaker 300:10:03Because GAAP net income includes a number of non cash expenses, we also use adjusted EBITDA as a good indicator of operating performance of the core business. Q2 adjusted EBITDA was a positive $5,000,000 compared to Q1 adjusted EBITDA of $7,400,000 The change was primarily due to the impact of lower product sales and increase in inventory write down expense. Please refer to our press release for additional reconciliation of our adjusted EBITDA results. Crossing over to cash flow and our balance sheet. We generated $7,400,000 in cash flow from operations in the 2nd quarter on top of the $7,500,000 in the 1st quarter. Speaker 300:10:51As we have previously noted, quarterly cash flows will fluctuate due to the timing of working capital, royalties and interest payments as well as shift in product mix from IndusInd to Robidone. Cash and short term investments at the end of the second quarter were 88,400,000 up from $80,700,000 in the 1st quarter and debt was unchanged at $40,000,000 In the Q2, we invested cash into short term investments, leading to a change in our balance sheet tables. Our total cash position referenced in our commentary today includes the line items cash and cash equivalents plus a new line item for short term investments. We are also maintaining our previously announced guidance for 2024, which provided for net product sales in a range of 110 dollars to $125,000,000 and adjusted EBITDA in a range of $20,000,000 to $30,000,000 With that, we will open the floor to questions from our covering research analyst. Operator, please go ahead with the instructions. Operator00:12:02We will now begin the question and answer session. Your first question comes from the line of Thomas Platten with Lake Street Capital Markets. Thomas, your line is now open. Speaker 400:12:25Hey, good afternoon. I appreciate you taking the questions. Brendan, maybe I could start with you. It's only been a couple of months, but I'm curious maybe if you could put some guardrails around what it was that excited you about the opportunity and what you've learned in the months you've been there that may or may not confirm what you thought or maybe made it better or worse, etcetera? Just trying to get some thoughts from you on that. Speaker 200:12:48Sure. Happy to, Thomas. Thanks for the question. So, I guess, maybe I'll answer the back half of the question and come back to the first part. So, after 71 days into the role, it's exactly what I thought it would be, I'm happy to say. Speaker 200:13:03And things are going according to how I thought they would go. And then I think I joined as I said in the beginning, I joined Assertio because I believe that there is an opportunity here to create great value. I think that everything that I said in my opening remarks about the balance sheet, about the people, about the commercial model, those have all been confirmed in my 1st 71 days. I think that the landscape in business development is starting to heat up a little bit. There's numerous potential deals out there to get. Speaker 200:13:40We'll see how those go. But I'm excited about Rolvadon. I think Rolvadon is growing nicely as we've shown. I think we'll continue to execute on Rolvedon. That will be our primary growth driver. Speaker 200:13:51There are other assets in the portfolio that I think we can get some modest growth of, as well as optimize some of the later stage assets. So, my take is the foundational business is stable and positioned to grow, and we can start adding to that and really position Assertio for growth going forward, which I'm very excited to do and very excited to be part of. Speaker 400:14:19And speaking of growth, you guys from a product sales perspective, you're $62,500,000 for the first half of the year, which would be about half of the top end of your guidance range. How are you thinking about modifying guidance as we go forward, if at all? Speaker 200:14:37So, I'll come back in November and give you a better take on that. Again, I'm 71 days in, so I want to make sure that I've got a good handle on where all of is. I think you just brought up a very good point, something that's fairly obvious. But we'll take a look at how the year is shaking out. And by the time we get to November, we will have completed 9 months of the year. Speaker 200:15:01So we'll take a look and see what we do with guidance at that point. Speaker 400:15:06Appreciate you taking the questions. Thanks so much. Speaker 200:15:09Sure. Thank you. Operator00:15:12Your next question comes from the line of Ram Selvaraju with H. C. Wainwright. Ram, your line is now open. Speaker 500:15:18Thanks so much for taking my questions and congrats on the fine performance in this quarter. Firstly, I was wondering if you could comment on your expectations regarding the number of generic competitors to Indocin that you expect to be on the market by the end of this year. If you can maybe give us some granularity on that, what your expectations are based on your internal projections? And the second question pertains to what may or may not be your overall strategy with regard to bringing in additional products. And if you anticipate these products to likely be more along the lines of products that you can promote on a virtual basis or if you are looking at any opportunities that would necessitate the deployment of a field sales force akin to what you're currently doing with Rolledon? Speaker 500:16:08Thank you. Speaker 200:16:11So, great questions. So, the question on generic competitors, this is always a tricky question because you never really know and I used to get this a lot on different assets when I was with Teva. But quite frankly, we expected another generic competitor on the market in July. That didn't happen. So we'll see. Speaker 200:16:32We don't really know much more than that other than the gold date came and went and that product has not been launched. So I guess you could say that every day that it's not, there's somewhat of a tailwind for indocin. Could we see another one by the end of the year? Potentially, our original thought was maybe we would see 2 or 3 generics on the market by end of this year. We may get lucky and we may just see the one. Speaker 200:17:01So it's hard to say, but our plan was for multiple. So, we'll see if there's any potential upside here, as we go through the year. But that's kind of how we're thinking about Indus and generics for the rest of the year. As far as overall product strategy, I mean, I think we're looking for something that capitalizes on our current commercial model. And we don't some of our later stage assets we do all non personal promotion. Speaker 200:17:31Rolodon actually, we as you know, we have a field force out there supporting Rolvedon. But a lot of assets require a little bit both field and omnichannel. So I don't think that we're looking for an asset that is exclusively one or the other. I think we're looking for an asset that builds on our capabilities, that is cash accretive, that has patent protection or exclusivity. I think those are the things that we're looking at and what we can execute with the cash reserves and balance that we have. Speaker 200:18:06So that's kind of where we're looking. And I don't think we're looking for an asset that requires a 500 to 1000 person sales force. I think we're looking at assets that really fit, our place in the market and where our core competencies are. Speaker 500:18:24Thank you. Sure. Operator00:18:29Your next question comes from the line of Nader Ramon with Maxim Group. Nader, Your line is now open. Speaker 600:18:36Hi. Thanks for taking my question and congrats on all the progress. Just sticking with the theme of BD, based on all the assets you sort of looked at thus far, what has been the gating factors in terms of closing and acquisition? Are you seeing valuations that are, in your opinion, too high? Or are you seeing do you think valuations for these assets are relatively appropriate currently? Speaker 600:19:00And what's sort of been stopping you from closing any of these acquisitions? And I guess my follow-up to that is also, what are you thinking of in terms of a structure of a transaction? Like how do you think of the relative value of using cash, equity or debt in a potential transaction? Speaker 200:19:16So I'll answer part 1 and I'll let A. J. Answer part 2. But as a buyer, valuations are always too high. So I'll just put that out there right now. Speaker 200:19:29But having said that, there are certainly things that are of interest to us that we believe are executable. And we're in active discussions with several different organizations and we'll see if any of those pan out. If they do, then we'll obviously come back with more detail. But I'm pleased with kind of what's in our BD view, so to say, and we'll see what comes out of it. There are some encouraging opportunities out there. Speaker 200:20:03I don't really want to say anymore. I can't really say anymore at this point. But there are things that we can do. And A. J, maybe that's what I'll hand it over to you and talk about how. Speaker 300:20:12Yes. Yes, Anas, thanks for the question. I'll probably echo what Brendan said in terms of how we're looking at assets that fit our capabilities. I think we're looking at acquisition size that fit our capabilities. Obviously, we'll start with from a capital perspective, we have several avenues, but we'll start with the lowest cost of capital, which for us will be our cash on our balance sheet. Speaker 300:20:34And I think from there, we have opportunities to look at either mix structured from a debt perspective. But I think we see ourselves utilizing cash first and then going down the line in terms of capital structure. Speaker 600:20:49Got it. Thank you for taking my questions. And once again, congrats on the progress. Speaker 200:20:54Thank you. Operator00:20:57Your next question comes from the line of Scott Henry with Alliance Group Partners. Scott, your line is Speaker 500:21:04now open. Speaker 700:21:05Thank you and good afternoon and congratulations, Brendan. Your first conference call almost over. Hopefully, I won't get too interesting. So for starters, Rolvedon, annualizing north of $60,000,000 in 2024, which is great. How when we think about 2025 and the competitive dynamics, would you still expect it to be a strong growth product at that stage? Speaker 700:21:40And by strong growth product, I think 20% or higher growth. Should we still think about it that way? And if you don't answer specifically, maybe if you could just talk about some of the factors that could tilt it higher or lower kind of than that threshold? Speaker 200:21:59Sure, Scott. Thank you for the question. And it's a good question. I mean, as you know, we are bullish on Rolled On. We think it has legs in the organization. Speaker 200:22:10We plan for it to be a growth asset, not for just this year, not just next year, but for the foreseeable future. So, yes, I do think that we'll see growth next year. And it's something that we constantly manage is that as we gain volume, you make you do different deals and put different contracts out there. So you have to balance the ASP erosion versus the volume growth. But I think we've got a good plan in place to do that. Speaker 200:22:40As I've looked at, the rest of this year and I look out through 2025, I see no reason why we can't continue to grow our rolloverdine. It's not a straight line growth though. It doesn't grow like that quarter over quarter. Some quarters will take bigger leaps than others. Traditionally, in the Q3, at least my experience has been in the oncology markets, you see somewhat of a flattening in Q3 just because a lot of patients doing chemotherapy schedule vacations and schedule their chemotherapy so they can have several weeks where they feel good to go on vacation with their family. Speaker 200:23:14So typically, Q3 can tend to be more of a flat quarter. But, yes, we see continued growth for rolvedon this year and next year and hopefully for the next several years. Speaker 700:23:26Okay, great. And my follow-up question maybe in multiple parts, but we'll see. For starters, OTREXUP and SYMPAZAN, any thoughts on how they did in the quarter? I didn't recall. We don't see the numbers in there, at least sequentially how they perform? Speaker 200:23:49Yes. So, I know A. J. Can give you the exact numbers, but just in general, those are a couple of the assets we're looking at as to what the potential is for those. I think that we're starting to see some modest regrowth of SYMPAZAN as we take a look at that as our kind of go to market strategy there and how we're getting the messaging out. Speaker 200:24:12SYMPAZAN is a great product and physicians love it, patients love it, caregivers love it. It occupies a very unique place in the market. And it's just a matter of making more physicians and patients aware of it. So we're looking at the most effective, most cost a SYMPAZAN, I think it's a great asset. In OTREXUP, that's just a kind of a matter of how we manage access against cost of goods so that patients have access to it and we can maintain or grow our share in that market as well. Speaker 200:24:46So both those are good assets for us. I think OTREXUP was relatively stable and flat from quarter to quarter and SYPAZAN we're starting to see some growth in the second half of the year. Speaker 300:24:58Yes, Scott. You'll see our 10 Q filed later today, but both of them in aggregate approximated 4,700,000 dollars And as I kind of said in my commentary, the entirety of our product portfolio revenue change between Q1 and Q2 was the plus and minus from Robidone and Hindustan. The rest of the product portfolio was fairly flat. Speaker 700:25:22Okay, great. And then you mentioned that the rolvedon same day dosing trial has completed enrollment, initial data expected later this year. Do you have a sense of that data already? If I recall, was that an unblinded trial? And I'm not asking you to disclose it, but I'd just like to be curious if you know, what is unknown about that data at this point in time? Speaker 200:25:53Yeah. So we haven't fully seen the data yet. So as I said, it will be presented at a major medical conference later this year. So we're still awaiting to see, the exact outcome of the data. What I will say is that this trial was never powered for a new indication, for same day dosing for rolvedon. Speaker 200:26:18We are hopeful that we will see some positive results that support same day dosing use. And we've submitted the abstract based on the preliminary data and more to come on that. But we're optimistic. Speaker 700:26:32Okay, great. Well, thank you for taking the questions. Absolutely. Operator00:26:39Your next question comes from the line of Jim Sidoti with Sidoti and Company. Jim, your line is now open. Speaker 500:26:46Hi. Thanks for taking the question. So just to follow-up on that same day dosing question. If the data is compelling, would you consider doing a larger trial to get the labeling? Speaker 200:27:00So Jim, thanks for the question. I mean, if the data is real compelling, we'll take a look at it and see if there is value in doing a larger trial, what that investment would be required to do that and the hopes of getting that not just added to guidelines, but adding it to our label. We'll see. We'll make that determination once we see the full results of the trial and obviously talk with some key opinion leaders and assess where we go from there. Speaker 500:27:29Okay. And for Robidone, A. J, were there any inventory step up charges in the quarter? Speaker 300:27:36There was an inventory step up charge. It was about $400,000 Speaker 500:27:42Okay. And can you just repeat what the write down charge you took was? Speaker 300:27:49Yes. The inventory write down charges that we took during the quarter were for our late stage product assets, and the increase quarter over quarter was approximately $1,000,000 Speaker 500:28:01Okay. All right. Thank you. Operator00:28:07That concludes our Speaker 200:28:17us today. As I said in my opening remarks, I'm excited to be here at Assertio and I hope that today's call has illustrated not only the solid execution and cash generating business that we have today, but also our commitment to finding the right assets to help move Assertio into the next chapter as we work to further scale the business and create value. We will be attending a number of conference and roadshow events in the coming months, and I look forward to the opportunity to engage with our stockholders. If you would like to arrange a meeting at one of these events or an update call with management, please contact Matt Kreps directly using his information provided in the press release and we will be happy to schedule a time. And thank you all once again for joining us today. Speaker 200:29:00Take care. Have a good evening. Operator00:29:03Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by